Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
16 05 2019
16 05 2019
Historique:
received:
15
10
2018
accepted:
22
01
2019
pubmed:
17
2
2019
medline:
14
1
2020
entrez:
17
2
2019
Statut:
ppublish
Résumé
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of lymphoma that, like other Hodgkin lymphomas, has historically been treated aggressively. However, in most cases, NLPHL has an indolent course, which raises the question of to what extent these patients require aggressive upfront treatment. We describe the management and outcomes of consecutive NLPHL patients diagnosed at Memorial Sloan Kettering Cancer Center (MSK), with a focus on evaluating active surveillance. All patients aged 16 years or older diagnosed and followed at MSK between 1974 and 2016 were included. Treatment outcomes were compared between management with active surveillance and other strategies. We identified 163 consecutive patients who were treated with radiotherapy alone (46%), active surveillance (23%), chemotherapy (16%), combined modality (12%), or rituximab monotherapy (4%). Median follow-up was 69 months. Five-year progression-free survival (PFS), second PFS (PFS2), and overall survival (OS) estimates were 85% (95% confidence interval [CI], 78-90), 97% (95% CI, 92-99), and 99% (95% CI, 95-100), respectively. Only 1 of 7 deaths was lymphoma related. Patients managed with active surveillance had slightly shorter PFS than those receiving any active treatment, with 5-year PFS of 77% (95% CI, 56-89) vs 87% (95% CI, 79-92;
Identifiants
pubmed: 30770396
pii: S0006-4971(20)42551-0
doi: 10.1182/blood-2018-10-877761
pmc: PMC7022227
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2121-2129Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 by The American Society of Hematology.
Références
J Clin Oncol. 2003 Aug 1;21(15):2948-52
pubmed: 12885814
Blood. 2007 Mar 1;109(5):1857-61
pubmed: 17105812
J Clin Oncol. 2008 Jan 20;26(3):434-9
pubmed: 18086799
Lancet. 2003 Aug 16;362(9383):516-22
pubmed: 12932382
Blood. 2017 Jul 27;130(4):472-477
pubmed: 28522441
Leukemia. 2016 Jun;30(6):1425-7
pubmed: 26585412
Cancer. 2010 Feb 1;116(3):631-9
pubmed: 20029973
Blood. 2011 Oct 27;118(17):4585-90
pubmed: 21873543
J Clin Oncol. 2016 Jul 10;34(20):2372-9
pubmed: 27185849
J Clin Oncol. 1999 Mar;17(3):776-83
pubmed: 10071266
J Clin Oncol. 2015 Sep 10;33(26):2857-62
pubmed: 26240235
Ann Hematol. 2016 Feb;95(3):417-23
pubmed: 26732883
J Clin Oncol. 2010 Feb 10;28(5):793-9
pubmed: 20048177
J Pediatr Hematol Oncol. 2003 Sep;25(9):684-7
pubmed: 12972802
Leuk Lymphoma. 1997 Jul;26(3-4):359-68
pubmed: 9322899
Cancer. 2007 Jul 1;110(1):179-85
pubmed: 17526010
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Blood. 2014 Jun 5;123(23):3567-73
pubmed: 24713929
Haematologica. 2015 Dec;100(12):1579-86
pubmed: 26430172
Cancer. 2002 Mar 15;94(6):1731-8
pubmed: 11920535
N Engl J Med. 2015 Dec 24;373(26):2499-511
pubmed: 26699166
Blood. 2013 Dec 19;122(26):4246-52; quiz 4292
pubmed: 24100447
Lancet Oncol. 2014 Apr;15(4):424-35
pubmed: 24602760
N Engl J Med. 1998 Nov 19;339(21):1506-14
pubmed: 9819449
J Clin Oncol. 2010 Jan 1;28(1):136-41
pubmed: 19933914
Cancer. 2015 Jun 1;121(11):1737-46
pubmed: 25336142
Am J Hematol. 2015 Jun;90(6):E103-10
pubmed: 25715900
Leuk Lymphoma. 2006 Aug;47(8):1504-10
pubmed: 16966260
Am J Surg Pathol. 2003 Oct;27(10):1346-56
pubmed: 14508396
J Exp Med. 2008 Sep 29;205(10):2251-68
pubmed: 18794340
Ann Oncol. 2014 Sep;25 Suppl 3:iii70-5
pubmed: 25185243
Blood. 2016 Apr 21;127(16):1960-6
pubmed: 26837698
J Clin Oncol. 2014 Mar 20;32(9):912-8
pubmed: 24516013